Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Cardiology | Family Medicine | Hematology | Internal Medicine | Journal

Back to Journal Articles

Erythropoietin Improves Blood Flow in Ischemic Legs

Last Updated: June 18, 2009.

 

Delivery by gelatin microspheres avoids unfavorable effects of systemic delivery

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
When delivered by gelatin microspheres, the angiogenic factor erythropoietin can safely improve blood flow in a mouse model of peripheral arterial disease, according to a study in the June 23 issue of the Journal of the American College of Cardiology.

THURSDAY, June 18 (HealthDay News) -- When delivered by gelatin microspheres, the angiogenic factor erythropoietin can safely improve blood flow in a mouse model of peripheral arterial disease, according to a study in the June 23 issue of the Journal of the American College of Cardiology.

Longhu Li, M.D., from Gifu University Graduate School of Medicine in Japan, and colleagues ligated the right femoral arteries of mice to create ischemia, then injected the right hind limb muscles with erythropoietin-immersed gelatin hydrogel microspheres or with saline, microspheres without erythropoietin, or erythropoietin.

After eight weeks, the researchers found that blood flow to the ischemic leg improved significantly in mice receiving the erythropoietin microspheres. Capillary and arteriolar densities significantly increased in these mice, with no changes in hemoglobin level or endothelial progenitor cells. The treatment was associated with increases in the level of the erythropoietin receptor and downstream signaling mediators.

"At present, both erythropoietin and gelatin hydrogels are already in use in the clinical setting, with safety clearly established, so the unfavorable systemic effect of erythropoietin is avoidable with this method," Li and colleagues conclude. "We believe that this therapy is safer, less invasive, and more promising compared with previous therapeutic angiogenesis and is readily applicable to patients suffering from peripheral artery disease."

Abstract
Full Text (subscription or payment may be required)

Copyright © 2009 ScoutNews, LLC. All rights reserved.


Previous: AMA: Policy Statement Supports Health Care Reform Next: Macrophage Marker Linked to Survival in Melanoma

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.